Evidence map›Paper›PMID 33249459›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021

Cerebrospinal Fluid Lactate as a Prognostic Marker of Disease Severity and Mortality in Cryptococcal Meningitis.

Mahsa Abassi, Ananta S Bangdiwala, Edwin Nuwagira, Kiiza Kandole Tadeo, Michael Okirwoth, Darlisha A Williams, Edward Mpoza, Lillian Tugume, Kenneth Ssebambulidde, Kathy Huppler Hullsiek and 5 more

Open access · greenAbstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Energy metabolism in health and diseases.Signal transduction and targeted therapy · 2025
    Review
  4. Article
  5. Article
  6. Cryptococcal meningitis.Nature reviews. Disease primers · 2023
    Review
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Mahsa AbassiInfectious Diseases Institute, Makerere University, Kampala, Uganda.
Ananta S BangdiwalaUniversity of Minnesota, Minneapolis, Minnesota, USA.
Edwin NuwagiraMbarara University of Science and Technology Mbarara, Uganda.
Kiiza Kandole TadeoInfectious Diseases Institute, Makerere University, Kampala, Uganda.
Michael OkirwothInfectious Diseases Institute, Makerere University, Kampala, Uganda.
Darlisha A WilliamsInfectious Diseases Institute, Makerere University, Kampala, Uganda.
Edward MpozaInfectious Diseases Institute, Makerere University, Kampala, Uganda.
Lillian TugumeInfectious Diseases Institute, Makerere University, Kampala, Uganda.
Kenneth SsebambuliddeInfectious Diseases Institute, Makerere University, Kampala, Uganda.
Kathy Huppler HullsiekUniversity of Minnesota, Minneapolis, Minnesota, USA.
Abdu K MusubireInfectious Diseases Institute, Makerere University, Kampala, Uganda.
Conrad MuzooraMbarara University of Science and Technology Mbarara, Uganda.
Joshua RheinInfectious Diseases Institute, Makerere University, Kampala, Uganda.
David B MeyaInfectious Diseases Institute, Makerere University, Kampala, Uganda.
David R BoulwareUniversity of Minnesota, Minneapolis, Minnesota, USA.
Makerere University · UGInfectious Diseases Institute · UGUniversity of Minnesota · USMbarara University of Science and Technology · UG

Funding

Improving Diagnostics and Neurocognitive Outcomes in HIV/AIDS-related MeningitisR01NS086312 · NINDS · UNIVERSITY OF MINNESOTA · PI David R Boulware, David Bisagaya Meya · 2013 to 2026
$8.3M
Infectious Disease Training in Clinical InvestigationT32AI055433 · NIAID · UNIVERSITY OF MINNESOTA TWIN CITIES · PI David R Boulware · 2003 to 2026
$6.1M
Northern/Pacific Universities Global Health Research Training ConsortiumR25TW009345 · FIC · UNIVERSITY OF WASHINGTON · PI KOLARS, JOSEPH C., NERURKAR, VIVEK RAMCHANDRA · 2012 to 2016
$5.9M
Targeting Neuropathogenesis of Altered Mental Status to Improve Survival in Cryptococcal MeningitisK23NS122601 · NINDS · UNIVERSITY OF MINNESOTA · PI ABASSI, MAHSA · 2021 to 2025
$1.1M
Improving Outcomes of HIV-Associated Cryptococcosis in Resource-Limited SettingsK01TW010268 · FIC · UNIVERSITY OF MINNESOTA · PI RHEIN, JOSHUA R · 2016 to 2020
$703k
Epidemiology, Immunopathogenesis, and Outcomes of Non-traumatic Spinal Cord Injury in UgandaK43TW010718 · FIC · INFECTIOUS DISEASES INSTITUTE · PI MUSUBIRE, ABDU KISEKKA · 2017 to 2021
$514k
FIC NIH HHS K01 TW010268FIC NIH HHS K43 TW010718FIC NIH HHS R25 TW009345Medical Research Council MR/M007413/1NIAID NIH HHS T32 AI055433NINDS NIH HHS K23 NS122601NINDS NIH HHS R01 NS086312Wellcome TrustWellcome Trust 107742/Z/15/Z
6 · The paper itself

Abstract

backgroundCerebrospinal fluid (CSF) lactate levels can be used to differentiate between bacterial and viral meningitis. We measured CSF lactate in individuals with cryptococcal meningitis to determine its clinical significance.

methodsWe measured point-of-care CSF lactate at the bedside of 319 Ugandan adults living with human immunodeficiency virus at diagnosis of cryptococcal meningitis. We summarized demographic variables and clinical characteristics by CSF lactate tertiles. We evaluated the association of CSF lactate with clinical characteristics and survival.

resultsIndividuals with high CSF lactate >5 mmol/L at cryptococcal diagnosis more likely presented with altered mental status (P < .0001), seizures (P = .0005), elevated intracranial opening pressure (P = .03), higher CSF white cells (P = .007), and lower CSF glucose (P = .0003) compared with those with mid-range (3.1 to 5 mmol/L) or low (≤3 mmol/L) CSF lactate levels. Two-week mortality was higher among individuals with high baseline CSF lactate >5 mmol/L (35%; 38 of 109) compared with individuals with mid-range (22%; 25 of 112) or low CSF lactate (9%; 9 of 97; P =<.0001). After multivariate adjustment, CSF lactate >5 mmol/L remained independently associated with excess mortality (adjusted hazard ratio = 3.41; 95% confidence interval, 1.55-7.51; P = .002). We found no correlation between baseline CSF lactate levels and blood capillary lactate levels.

conclusionsBaseline point-of-care CSF lactate levels are a prognostic marker of disease severity and mortality in cryptococcal meningitis. Individuals with an elevated baseline CSF lactate level are more likely to present with altered mental status, seizures, and elevated CSF opening pressure and are at a greater risk of death. Future studies are needed to determine targeted therapeutic management strategies in persons with high CSF lactate.

Indexed as

CryptococcusMeningitis, CryptococcalCerebrospinal FluidHumansLactic AcidPrognosisSeverity of Illness IndexLactic Acidcerebrospinal fluidcryptococcal meningitislactic acidmortalityprognostic marker

Identifiers

PMID33249459
PMCPMC8563209
OpenAlexW3108140269

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.